Co-sulfamethoxazole Tablets

This product is a sulfonamide antibacterial drug, a compound preparation of sulfamethoxazole (SMZ) and trimethoprim (TMP). It has good antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Salmonella, Proteus, Morganella, Shigella and other Enterobacteriaceae, gonococci, Neisseria meningitidis, and Haemophilus influenzae. In particular, the antibacterial effect on Escherichia coli, Haemophilus influenzae, and Staphylococcus aureus is significantly enhanced compared with SMZ alone. In addition, it also has good antimicrobial activity against Chlamydia trachomatis, Nocardia asteroides, protozoa, and Toxoplasma gondii in vitro. The mechanism of action of this product is: SMZ acts on dihydrofolate synthase, interfering with the first step of folic acid synthesis, and TMP acts on the second step of folic acid anabolism, selectively inhibiting the action of dihydrofolate reductase. The combination of the two can double-block the folic acid metabolism of bacteria. The synergistic antibacterial effect of this product is stronger than that of a single drug, and the number of resistant strains to it is reduced. However, in recent years, the resistance of bacteria to this product has also been increasing.

This product is a compound preparation, and its components are: each tablet contains 0.4g of sulfamethoxazole and 80mg of trimethoprim.

This product is white tablets.

In recent years, since many common clinical pathogens are often resistant to this product, the treatment of bacterial infections needs to refer to the drug sensitivity results. The main indications of this product are the following infections caused by sensitive strains: 1. Urinary tract infections caused by sensitive strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Proteus vulgaris and Morganella. 2. Acute otitis media in children over 2 years old caused by Streptococcus pneumoniae or Haemophilus influenzae. 3. Acute exacerbation of chronic bronchitis in adults caused by Streptococcus pneumoniae or Haemophilus influenzae. 4. Intestinal infections and Shigella infections caused by sensitive strains of Shigella flexneri or Shigella sonnei. 5. This product is the first choice for the treatment of Pneumocystis carinii pneumonia. 6. For the prevention of Pneumocystis carinii pneumonia, it can be used in patients with a history of at least one attack of Pneumocystis carinii, or in patients with HIV

1. Common dosage for adults: 160 mg of trimethoprim and 800 mg of sulfamethoxazole for bacterial infection, taken once every 12 hours. For the treatment of Pneumocystis carinii pneumonia, 3.75-5 mg/kg of trimethoprim and 18.75-25 mg/kg of sulfamethoxazole are taken once every 6 hours. Preventive medication for adults: initially give 160 mg of trimethoprim and 800 mg of sulfamethoxazole twice a day, then take the same dose once a day, or 3 times a week. 2. Common dosage for children: prohibited for infants under 2 months old. For the treatment of bacterial infection, infants over 2 months old and weighing less than 40 kg are given SMZ 20-30 mg/kg and TMP 4-6 mg/kg orally according to body weight, once every 12 hours; the dosage for children weighing >40 kg is the same as the common dosage for adults. For the treatment of parasitic infections such as Pneumocystis carinii pneumonia, SMZ 18.75-25 mg/kg and TMP 3.75-5 mg/kg are taken orally according to body weight once every 6 hours. The course of treatment for acute exacerbation of chronic bronchitis is at least 10-14 days; the course of treatment for urinary tract infection is 7-10 days; the course of treatment for bacillary dysentery is 5-7 days; the course of treatment for acute otitis media in children is 10 days; the course of treatment for Pneumocystis carinii pneumonia is 14-21 days.

1. Allergic reactions are relatively common and may manifest as drug rashes. In severe cases, exudative erythema multiforme, exfoliative dermatitis, and epidermolysis bullosa atrophic dermatitis may occur; there are also serum sickness-like reactions such as photosensitivity reactions, drug fever, joint and muscle pain, and fever. Anaphylactic shock is occasionally seen. 2. Neutropenia or deficiency, thrombocytopenia, and aplastic anemia. Patients may present with sore throat, fever, pallor, and bleeding tendency. 3. Hemolytic anemia and hemoglobinuria. This is prone to occur in patients who lack glucose-6-phosphate dehydrogenase after using sulfonamides, and is more common in newborns and children than in adults. 4. Hyperbilirubinemia and neonatal kernicterus. Because this product competes with bilirubin for protein binding sites, it can cause an increase in free bilirubin. Newborns have imperfect liver function and are not suitable for them.

1. Patients who are allergic to SMZ and TMP are contraindicated to use this product. 2. Since this product blocks the metabolism of folic acid and aggravates the folate deficiency in patients with megaloblastic anemia, patients with this disease are contraindicated to use this product. 3. Pregnant and lactating women are contraindicated to use this product. 4. Infants under 2 months old are contraindicated to use this product. 5. Patients with severe liver and kidney damage are contraindicated to use this product.

Precautions for children: Since this product can compete with bilirubin for binding sites on plasma proteins, and the acetyltransferase system of newborns is not fully developed, the increased free blood concentration of sulfonamide can increase the risk of kernicterus. Therefore, the use of this type of drug in newborns and infants under 2 months old is contraindicated. Children are in the growth and development period, and their liver and kidney functions are not yet perfect, so the dosage should be reduced as appropriate. Precautions for pregnancy and lactation: It is not clear yet. Precautions for the elderly: Elderly patients have an increased chance of serious adverse reactions when using this product, such as severe skin allergic reactions such as rash, and blood system abnormalities such as bone marrow suppression, leukopenia and thrombocytopenia. It is more likely to occur when using diuretics at the same time. Therefore, elderly patients should avoid using it, and when there is an indication, the pros and cons should be weighed before deciding.

1. The combined use of urine alkalinizing drugs can increase the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with para-aminobenzoic acid, which can replace this product for bacterial uptake, and the two are antagonistic. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action time or toxic reactions. Therefore, when these drugs are used at the same time as this product, or when used after the application of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. The combined use with bone marrow suppressive drugs may enhance the adverse reactions of such drugs to the hematopoietic system. For example, leukopenia and thrombocytopenia, etc. If there is an indication for the combined use of the two drugs, the possible toxic reactions should be closely observed. 5. Long-term combined use with contraceptives (estrogens) can reduce the reliability of contraception and increase the chance of extramenstrual bleeding. 6. When used in combination with thrombolytic drugs, their potential toxic effects may be increased. 7. When used in combination with hepatotoxic drugs, the incidence of hepatotoxicity may increase. Liver function should be monitored for such patients, especially those who have been taking the drug for a long time and have a history of liver disease. 8. When used in combination with photosensitive drugs, photosensitization may be additive. 9. Patients receiving this product have an increased need for vitamin K. 10. It should not be used in combination with methenamine, because methenamine can decompose in acidic urine to produce formaldehyde, which can form insoluble precipitates with this product. This increases the risk of crystalluria. 11. This product can replace the plasma protein binding site of phenylbutazone, and when the two are used together, the effect of phenylbutazone can be enhanced. 12. When sulfinpyrazone is used in combination with this product, the latter's secretion from the renal tubules can be reduced. The prolonged increase in its blood concentration is prone to toxic reactions. Therefore, the dose of this product may need to be adjusted during or after the application of sulfinpyrazone. When the course of sulfinpyrazone treatment is long, the blood concentration of this product should be monitored to help adjust the dose and ensure safe medication. 13. TMP in this product can inhibit the metabolism of warfarin and enhance its anticoagulant effect. 14. TMP in this product can increase nephrotoxicity when used in combination with cyclosporine. 15. When rifampicin is used in combination with this product, the clearance of TMP in this product can be significantly increased and the serum half-life can be shortened. 16. It is not suitable to be used in combination with anti-tumor drugs and 2,4-diaminopyrimidine drugs, nor should it be used between courses of treatment with other folic acid antagonists, because it may cause bone marrow aplasia or megaloblastic anemia. 17. It is not suitable to be used in combination with dapsone, because the blood concentration of both dapsone and TMP in this product can be increased. The increase in dapsone concentration increases and aggravates adverse reactions, especially the occurrence of methemoglobinemia. 18. Avoid using it in combination with penicillins, because this product may interfere with the bactericidal effect of such drugs. [Storage] Keep it in a dark and sealed place.

Keep away from light and store in sealed container.

Each tablet contains sulfamethoxazole 0.4 g; trimethoprim 0.08 g

24 months

Xuchang High Tech Pharmaceutical Co., Ltd.

• Founded in:

  2003-04-17

• Address:

  No. 2111, Laodong South Road, Weidu District, Xuchang City, Henan Province

• Tax NO.:

  91411000749213665Q

• Registered Funds:

  1 million yuan

• Email:

  Log in to view